Clinical trials: Leucovorin
Metastatic Gastric Cancer
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
Elderly patients are generally underrepresented in the study populations of combination chemotherapy trials. In gastric cancer patients, oxaliplatin has shown a more favorable toxicity profile than cisplatin.
- Trial name
- MATURE (NCT02002195)
- Testing
- FOLFOX, Capecitabine
- Where
- 2 sites in Italy
- Volunteers
- 47 people
- Sponsor
- International Group of Endovascular Oncology
Locally Advanced Rectal Cancer
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.
- Trial name
- NCT03503630
- Testing
- COMPOUND 2055269, Radiation Therapy, mFOLFOX
- Where
- 3 sites in Jordan, Lebanon
- Volunteers
- 44 people
- Sponsor
- Ali Shamseddine
Colorectal Cancer
S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more cancer cells.
- Trial name
- NCT00002593
- Testing
- fluorouracil, leucovorin calcium, levamisole hydrochloride
- Where
- 60 sites in United States, Canada and 2 more
- Volunteers
- 1,135 people
- Sponsor
- SWOG Cancer Research Network
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Colorectal, Colorectal Cancer
Oxaliplatin Pharmacokinetics With and Without Ca2+/MG2+ Infusion in Colorectal Cancer Patients
The investigators hypothesize that Ca2+/MG2+ infusions will not have a significant effect on oxaliplatin pharmacokinetics.
- Conditions
- Neoplasms, Colorectal, Colorectal Cancer, Colorectal Carcinoma
- Trial name
- NCT01157052
- Testing
- (supplement) Calcium and Magnesium
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- AHS Cancer Control Alberta
HCC, Precision Therapy
Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models
Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time of diagnosis and cannot be surgically resected.
- Trial name
- NCT06463444
- Testing
- HAIC + Tislelizumab +lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chen Xiaoping
HER2 Negative Gastric Cancer
Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma
The purpose of the study is to compare efficacy and safety of palliative chemotherapy EOX and mDCF regimens in the first-line treatment of patients with advanced HER2-negative gastric and gastroesophageal junction (GEJ)…
- Trial name
- NCT02445209
- Testing
- EOX, mDCF
- Volunteers
- 56 people
- Sponsor
- Jagiellonian University
Locally Advanced Colorectal Carcinoma
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
The goal of this clinical trial is to compare the efficacy and safety of the combination of immune checkpoint inhibitors (ICIs) and FOLFOX regimen compared to FOLFOX regimen alone in the neoadjuvant chemotherapy of locally…
- Trial name
- NCT06154538
- Testing
- Immune checkpoint inhibitor, FOLFOX regimen
- Where
- 3 sites in China
- Volunteers
- 170 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer
Registry Multicenter, prospective observational study Observe adverse events and efficacy in recruited patients for 3 years under real world settings.
- Trial name
- NCT03286738
- Testing
- FOLFIRI, target agent
- Where
- South Korea
- Volunteers
- 1,800 people
- Sponsor
- Joong Bae Ahn
Biliary Tract Neoplasms
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
To evaluate the following items in patients with locally advanced and metastatic biliary tract cancer receiving SLOG or GC treatment, Primary objective: 6-month progression-free survival rate Secondary objectives: Objective…
- Trial name
- NCT03406299
- Testing
- Tegafur, Leucovorin, Oxaliplatin
- Where
- Taiwan
- Volunteers
- 92 people
- Sponsor
- National Health Research Institutes, Taiwan
Metastatic Colorectal Cancer
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan…
- Trial name
- NCT00508404
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 154 people
- Sponsor
- Amgen
Advanced Solid Tumors
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Immune therapies work with the body's immune system to treat a number of cancers. They work with T-cells, a type of white blood cell, to target and attack specific tumors.
- Trial name
- NCT05083481
- Testing
- ASP1570, pembrolizumab, Trifluridine + Tipiracil
- Where
- 30 sites in United States, China and 4 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer
OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with nivolumab followed by FOLFIRI reintroduction, versus FOLFIRI as maintenance…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer
- Trial name
- TEDOPAM (NCT03806309)
- Testing
- FOLFIRI, OSE2101
- Where
- 28 sites in France
- Volunteers
- 106 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
This is a Phase 2 multicenter, randomized, parallel arms, double-blind study of vanucizumab to evaluate the efficacy and safety of vanucizumab in combination with oxaliplatin, folinic acid, and 5-fluorouracil (5-FU) (mFOLFOX-6)…
- Trial name
- McCAVE (NCT02141295)
- Testing
- 5-FU, Bevacizumab, Folinic acid
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 197 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major…
- Trial name
- NCT02774187
- Testing
- Sorafenib, Hepatic arterial infusion chemotherapy, Folfox Protocol
- Where
- 5 sites in China
- Volunteers
- 247 people
- Sponsor
- Sun Yat-sen University
Metastatic Gastric Cancer
Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer
This survey is a single arm study to assess the effect of home parenteral nutrition on overall survival, cycles of salvage chemotherapy completed, side effects of salvage chemotherapy, quality of life, nutritional status…
- Trial name
- NCT03121807
- Testing
- Oliclinomel N4 Per bag 1.5 L, Oxaliplatin, 5Fluorouracil
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Advanced Upper Gastrointestinal Tract Adenocarcinoma
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell…
- Trial name
- STAR-221 (NCT05568095)
- Testing
- Domvanalimab, Zimberelimab, Capecitabine
- Where
- 168 sites in United States, Argentina and 27 more
- Volunteers
- 1,040 people
- Sponsor
- Arcus Biosciences, Inc.
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
This single arm study will assess the efficacy and safety of a combination of modified FOLFIRI (irinotecan, 5-FU and leucovirin), Avastin and cetuximab in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00577109
- Testing
- bevacizumab [Avastin], Irinotecan, Leucovorin
- Where
- 3 sites in Brazil
- Sponsor
- Hoffmann-La Roche
Rectal Cancer
Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer
GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous pelvic radiotherapy for the primary rectal cancer.
- Trial name
- GRECCAR15 (NCT03879109)
- Testing
- Chemotherapy FOLFIRINOX, 6 cycles, Radiochemotherapy, Surgery
- Where
- 13 sites in France
- Volunteers
- 58 people
- Sponsor
- University Hospital, Bordeaux
Colorectal Cancer
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared…
- Trial name
- NCT00115765
- Testing
- Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy
- Volunteers
- 1,053 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.